How LGD-4033 works
LGD-4033, a novel nonsteroidal, oral selective androgen receptor modulator, binds to the androgen receptor with high affinity and selectivity. It demonstrates anabolic activity in muscles,
anti-resorptive and anabolic activity in bones and a robust selectivity for muscle and bone versus prostate and sebaceous glands. LGD-4033 has recently completed a Phase I Multiple Ascending Dose
study in healthy volunteers. This randomized, double-blind, placebo-controlled Phase I study established the safety and tolerability up to doses of 22 mg per day.
LGD-4033 Uses